secwatch.observer — SEC 8-K summary
======================================

Issuer:     Axsome Therapeutics, Inc. (AXSM)
CIK:        0001579428
Form:       8-K
Filed at:   2025-05-05T23:59:59+00:00
Accession:  0000950170-25-063158
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Axsome Q1 total net product revenue $121.5M (+62% YoY); SYMBRAVO launch on track for June 2025
--------------------------------------------------------------------------------

- Total net product revenue $121.5M (+62% YoY); AUVELITY $96.2M (+80%) and SUNOSI $25.2M (+17%).
- Net loss improved to $59.4M ($1.22/sh) from $68.4M ($1.44/sh) in Q1 2024; includes $23.3M stock comp.
- SYMBRAVO approved for acute migraine; commercial launch on track for June 2025.
- NDA submitted for AXS-14 (fibromyalgia); sNDA for AXS-05 (AD agitation) on track for Q3 2025; AXS-12 (narcolepsy) NDA in H2 2025.
- Cash $300.9M; company believes sufficient to fund operations to cash flow positivity.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1579428/000095017025063158/0000950170-25-063158-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1579428/000095017025063158/axsm-20250505.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-063158

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer